$82.4 Million is the total value of CAXTON CORP's 25 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 56.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MEIP | Sell | MEI PHARMA INC | $9,132,000 | -42.4% | 3,459,124 | -6.0% | 11.08% | -24.4% |
| AMLP | Sell | ALPS ETF TRalerian mlp | $3,596,000 | -19.5% | 411,873 | -1.6% | 4.36% | +5.6% |
| JBGS | Sell | JBG SMITH PPTYS | $778,000 | -48.7% | 22,349 | -45.7% | 0.94% | -32.6% |
| KURA | Sell | KURA ONCOLOGY INC | $461,000 | -24.1% | 32,828 | -5.4% | 0.56% | -0.4% |
| Sell | INTEC PHARMA LTD JERUSALEM | $318,000 | -12.6% | 42,236 | -34.4% | 0.39% | +14.9% | |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $149,000 | -33.8% | 13,948 | -5.3% | 0.18% | -13.0% |
| CTIC | Sell | CTI BIOPHARMA CORP | $91,000 | -78.7% | 123,941 | -37.2% | 0.11% | -72.2% |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -111,898 | -100.0% | -0.18% | – |
| CACC | Exit | CREDIT ACCEP CORP MICH | $0 | – | -459 | -100.0% | -0.19% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -111,217 | -100.0% | -0.20% | – |
| FPACU | Exit | FAR PT ACQUISITION CORPunit 06/01/2025 | $0 | – | -23,030 | -100.0% | -0.22% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -72,967 | -100.0% | -0.26% | – |
| TPIV | Exit | TAPIMMUNE INC | $0 | – | -81,540 | -100.0% | -0.68% | – |
| UHAL | Exit | AMERCO | $0 | – | -2,700 | -100.0% | -0.89% | – |
| PCG | Exit | PG&E CORP | $0 | – | -22,500 | -100.0% | -0.96% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -51,279 | -100.0% | -13.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.